322 related articles for article (PubMed ID: 21959288)
1. The influence of the 'organizational factor' on compound quality in drug discovery.
Leeson PD; St-Gallay SA
Nat Rev Drug Discov; 2011 Sep; 10(10):749-65. PubMed ID: 21959288
[TBL] [Abstract][Full Text] [Related]
2. Molecular inflation, attrition and the rule of five.
Leeson PD
Adv Drug Deliv Rev; 2016 Jun; 101():22-33. PubMed ID: 26836397
[TBL] [Abstract][Full Text] [Related]
3. The influence of lipophilicity in drug discovery and design.
Arnott JA; Planey SL
Expert Opin Drug Discov; 2012 Oct; 7(10):863-75. PubMed ID: 22992175
[TBL] [Abstract][Full Text] [Related]
4. Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety.
Meanwell NA
Chem Res Toxicol; 2011 Sep; 24(9):1420-56. PubMed ID: 21790149
[TBL] [Abstract][Full Text] [Related]
5. The influence of lead discovery strategies on the properties of drug candidates.
Keserü GM; Makara GM
Nat Rev Drug Discov; 2009 Mar; 8(3):203-12. PubMed ID: 19247303
[TBL] [Abstract][Full Text] [Related]
6. A new paradigm for navigating compound property related drug attrition.
Barton P; Riley RJ
Drug Discov Today; 2016 Jan; 21(1):72-81. PubMed ID: 26404453
[TBL] [Abstract][Full Text] [Related]
7. Eliciting views of Australian pharmaceutical industry employees on collaboration and the concept of Quality Use of Medicines.
Wang N; Lipworth WL; Ritchie JE; Williams KM; Day RO
Intern Med J; 2011 Apr; 41(4):314-20. PubMed ID: 20403068
[TBL] [Abstract][Full Text] [Related]
8. The significance of acid/base properties in drug discovery.
Manallack DT; Prankerd RJ; Yuriev E; Oprea TI; Chalmers DK
Chem Soc Rev; 2013 Jan; 42(2):485-96. PubMed ID: 23099561
[TBL] [Abstract][Full Text] [Related]
9. The importance of triaging in determining the quality of output from high-throughput screening.
Jones P; McElroy S; Morrison A; Pannifer A
Future Med Chem; 2015; 7(14):1847-52. PubMed ID: 26419190
[No Abstract] [Full Text] [Related]
10. Trends in small molecule drug properties: A developability molecule assessment perspective.
Agarwal P; Huckle J; Newman J; Reid DL
Drug Discov Today; 2022 Dec; 27(12):103366. PubMed ID: 36122862
[TBL] [Abstract][Full Text] [Related]
11. Improving compound quality through in vitro and in silico physicochemical profiling.
van de Waterbeemd H
Chem Biodivers; 2009 Nov; 6(11):1760-6. PubMed ID: 19937820
[TBL] [Abstract][Full Text] [Related]
12. The European Lead Factory: An updated HTS compound library for innovative drug discovery.
van Vlijmen H; Ortholand JY; Li VM; de Vlieger JSB
Drug Discov Today; 2021 Oct; 26(10):2406-2413. PubMed ID: 33892142
[TBL] [Abstract][Full Text] [Related]
13. Recent advances in physicochemical and ADMET profiling in drug discovery.
Wang J; Skolnik S
Chem Biodivers; 2009 Nov; 6(11):1887-99. PubMed ID: 19937823
[TBL] [Abstract][Full Text] [Related]
14. Finding the sweet spot: the role of nature and nurture in medicinal chemistry.
Hann MM; Keserü GM
Nat Rev Drug Discov; 2012 Apr; 11(5):355-65. PubMed ID: 22543468
[TBL] [Abstract][Full Text] [Related]
15. Automating drug discovery.
Schneider G
Nat Rev Drug Discov; 2018 Feb; 17(2):97-113. PubMed ID: 29242609
[TBL] [Abstract][Full Text] [Related]
16. Relating molecular properties and in vitro assay results to in vivo drug disposition and toxicity outcomes.
Sutherland JJ; Raymond JW; Stevens JL; Baker TK; Watson DE
J Med Chem; 2012 Jul; 55(14):6455-66. PubMed ID: 22716080
[TBL] [Abstract][Full Text] [Related]
17. An analysis of the attrition of drug candidates from four major pharmaceutical companies.
Waring MJ; Arrowsmith J; Leach AR; Leeson PD; Mandrell S; Owen RM; Pairaudeau G; Pennie WD; Pickett SD; Wang J; Wallace O; Weir A
Nat Rev Drug Discov; 2015 Jul; 14(7):475-86. PubMed ID: 26091267
[TBL] [Abstract][Full Text] [Related]
18. The impact of assay technology as applied to safety assessment in reducing compound attrition in drug discovery.
Thomas CE; Will Y
Expert Opin Drug Discov; 2012 Feb; 7(2):109-22. PubMed ID: 22468913
[TBL] [Abstract][Full Text] [Related]
19. Improving Drug Design: An Update on Recent Applications of Efficiency Metrics, Strategies for Replacing Problematic Elements, and Compounds in Nontraditional Drug Space.
Meanwell NA
Chem Res Toxicol; 2016 Apr; 29(4):564-616. PubMed ID: 26974882
[TBL] [Abstract][Full Text] [Related]
20. A practical guide to secondary pharmacology in drug discovery.
Jenkinson S; Schmidt F; Rosenbrier Ribeiro L; Delaunois A; Valentin JP
J Pharmacol Toxicol Methods; 2020 Sep; 105():106869. PubMed ID: 32302774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
